Another NIH/NIAID-funded subproject is to improve and utilize an ELISA-based assay to monitor serum levels of soluble Siglec-8 as a potential biomarker of disease control and activity in an ongoing clinical study:  “Anti IL-5 and eosinophilic granulomatosis with polyangiitis (EGPA, formerly known as Churg Strauss syndrome): a double blind, placebo controlled trial” (U01 AI097073, Wechsler, PI)

We are also conducting a clinical trial involving an FDA-approved drug used to treat B cell malignancies can impact allergic reactivity.